Title	Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial
Author(s)	Mone, Fionnuala; Mulcahy, Cecilia; McParland, Peter; Breathnach, Fionnuala M.; Downey, Paul; McCormack, Dorothy; Culliton, Marie; Stanton, Alice; Cody, Fiona; Morrison, John J.; Daly, Sean; Higgins, John R.; Cotter, Amanda; Hunter, Alyson; Tully, Elizabeth C.; Dicker, Patrick; Alfirevic, Zarko; Malone, Fergal D.; McAuliffe, Fionnuala M.
Publication date	2018
Original citation	Mone, F., Mulcahy, C., McParland, P., Breathnach, F., Downey, P., McCormack, D., Culliton, M., Stanton, A., Cody, F., Morrison, J. J., Daly, S., Higgins, J., Cotter, A., Hunter, A., Tully, E. C., Dicker, P., Alfirevic, Z., Malone, F. D. and McAuliffe, F. M. (2018) 'Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial', BMJ Open, 8(7), e022056 (9pp). doi: 10.1136/bmjopen-2018-022056
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://bmjopen.bmj.com/content/8/7/e022056 http://dx.doi.org/10.1136/bmjopen-2018-022056 Access to the full text of the published version may require a subscription.
Rights	**© 2018, the Author(s) (or their employer(s). This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.** http://creativecommons.org/licenses/by-nc/4.0/
Item downloaded from	http://hdl.handle.net/10468/6940

Outcome	Low Dose Aspirin (Group 1) N=179	No Aspirin (Group 2) N=183	Screen and Treat (Group 3) N=184
Gestation at delivery (wks)	40.2 (1.4)	39.9 (1.9)	40.2 (1.5)
Birthweight (g)	3529 (469)	3478 (493)	3488 (502)
Birthweight <10th centile No. (%)	14 (8%)	18(10%)	25 (14%)
Mode of delivery No. (%) Spontaneous Instrumental Caesarean	 85 (47.5) 56 (31.3) 38 (21.2)	 95 (52.0) 47 (25.7) 41 (22.3)	 88 (47.8) 51 (27.7) 45 (24.5)
Pre-term delivery <34 weeks No. (%)	1 (0.6)	3 (1.6)	2 (1.1)
Spontaneous Labor No. (%)	96 (53.7)	103 (56.3)	101 (54.9)
Preeclampsia No. (%) Preeclampsia <34-weeks Preeclampsia <37-weeks	8 (4.5) 0 (0) 2 (1.1)	7 (3.8) 2 (1.1) 2 (1.1)	7 (3.8) 1 (0.5) 2 (1.1)
Abruption No. (%)	1 (0.5)	0 (0)	0 (0)
NICU admission No. (%)	9 (5.0)	7 (3.8)	9 (4.9)
Apgar < 7 No. (%)	5 (2.8)	2 (1.6)	3 (1.6)
Cord pH (arterial)	7.3 (0.1)	7.3 (0.1)	7.3 (0.1)
Outcome No. (%) Alive at 6-weeks Stillbirth Neonatal death	 177 (98.9) 2 (1.1) 0 (0)	 181 (99.0) 1 (0.5) 1 (0.5)	 182 (98.9) 0 (0) 2 (1.1)

Table S1: Secondary outcome measures

(Expressed as average and standard deviation unless otherwise stated)